KRAS and cholangiocarcinoma: The sorting of samples immediately visually confirmed the known association of the CCA Subtype 1 signature with FGFR2, IDH1/2, ARID1A, and BAP1 mutations, and negative correlation with KRAS and TP53 mutations [36]; this has not previously been demonstrated for this particular dataset.